Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
|
|
- Brice Mills
- 5 years ago
- Views:
Transcription
1 Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014
2 Background Approximately 10 to 20% patients have stage IIIA (N2) disease, with overall 5 year survival of 16% Marked variability in prognosis of patients with N2 disease Current staging does not differentiate between the degree and the bulk of N2 disease burden Mountain CF. Chest 1997; 111: Detterbeck FC et al. Chest 2013; 143(5) suppl):e191s-e210s Rusch VW et al. J Thorac Oncol 2007; 2(7):
3 Subgroups of N2 disease Ruckdescehl JC. Semin Oncol 1997; 111: Robinson et al. Chest 2007; 132: 243S-265S
4 Subgroups of N2 disease: 3 subgroups of stage III disease from Chest 2013 guidelines summary: 1. Infiltrative stage III (N2 and N3 disease where discrete nodes can no longer be clearly distinguished and measured), (radiographic group A, Silvestri et al) 2. Discrete N2/N3 involvement: patients in whom individual nodes can be distinguished (radiographic groups B and C, patients with central tumors or suspected N2 disease with chance of N2/N3 involvement of 20-25%) 3. Occult N2 disease despite preoperative staging: found intraoperatively or postoperatively to have N2 nodes Silvestri et al. Chest 2013; 143(5) (Suppl): e211s-e250s
5 Prognosis of N2 IIIA disease A. Survival of N2 disease varies widely depending on bulk and extent of N2 disease B. Many studies conducted in IIIA N2 NSCLC have been limited by a number of challenges: 1. Heterogeneous patient populations 2. Variable and at times imprecise staging (variable use of PET scans, variable pathologic confirmation of N2 disease) 3. Slow patient accrual C. Survival of clinical N2 disease patients varies widely by geographic region and database type Detterbeck FC et al. Chest 2013; 143(5) suppl):e191s-e210s Martins RG et al. JNCCN 2012; 10:
6 Detterbeck FC et al. Chest 2013; 143(5) suppl):e191s-e210s
7 National Cancer Database survival data for clinical stage IIIA-N2 disease Koshy MK et al. J Thor Oncology 2013; 8:
8 Treatment options for IIIA N2 disease 1. Induction chemotherapy followed by resection 2. Induction CRT followed by resection 3. Definitive CRT without surgery 4. Surgery followed by adjuvant chemotherapy/+/- RT
9 Does surgery have a role in the management of IIIA (N2) disease?
10 Point #1 Outcomes with primary surgery alone for patients with preoperatively identified N2 disease are poor
11 Pearson FGet al. J Thorac Cardiovasc Surg 83: 1-11, 1982
12 Ramnath N et al. Chest 2013; 143(5) (Suppl): e314s-e340s
13 Andre F, Le Chevalier et al. JCO 18: , 2000
14 Point #2 For patients with preoperatively identified N2 disease, preoperative chemotherapy followed by surgery is superior to surgery alone
15 Roth JA et al. J Natl Cancer Inst 86: , 1994
16 Rosell R et al. NEJM 1994; 330: 153-8
17 Andre F, Le Chevalier et al. JCO 18: , 2000
18 Ramnath N et al. Chest 2013; 143(5) (Suppl): e314se340s
19 Point #3 The available randomized phase III studies do not demonstrate survival benefit of surgery after neoadjuvant chemoradiotherapy treatment
20 INT 0139 Trial Design Albain K et al. Lancet 2009; 374: Diagram from Martins RG et al. JNCCN 2012; 10:
21 INT0139 survival results PFS of ITT population PFS 12.8 mo in group 1 vs 10.5 mo in group 2 OS of ITT population 5 year survival 27% in group 1 vs 20% in group 2 Albain K et al. Lancet 2009; 374:
22 INT0139: Overall survival in group 1 by pathological nodal substage Median survival for patients with N0 disease at surgery was 34.4 mo vs N+ disease of 26.4 mo Median survival was 7.9 months if no surgery Albain K et al. Lancet 2009; 374:
23 INT0139: lobectomy vs pneumonectomy Overall survival in ITT population: lobectomy subset of group 1 MST 33.6 mo group 1 vs 21.7 mo in group 2 Overall survival in ITT population: pneumonectomy subset of group 1 MST of 18.9 mo group 1 vs 29.4 mo group 2 Albain K et al. Lancet 2009; 374:
24 INT0139 Study did not meet primary endpoint of improved overall survival with trimodality therapy compared to bimodality therapy Patients with best results after surgery are those with pathological CR at thoracotomy and who undergo lobectomy Surgery associated with greater early mortality but with more late survivors By year 3, trend was seen towards better survival with surgery 38% vs 33% respectively Operative mortality was 17.6% for pts undergoing pneumonectomy and 1.1% for pts with lobectomy High surgical mortality in pts who underwent pneumonectomy may have offset benefit from surgery in group 1
25 EORTC 8941 Trial Design Van Meerbeeck et al. J Natl Cancer Inst 2007; 99: Diagram from Martins RG et al. JNCCN 2012; 10:
26 EORTC 8941 Overall Survival Van Meerbeeck et al. J Natl Cancer Inst 2007; 99:
27 EORTC 8941 Progression Free Survival Van Meerbeeck et al. J Natl Cancer Inst 2007; 99:
28 EORTC 8941 Exploratory Analyses Van Meerbeeck et al. J Natl Cancer Inst 2007; 99:
29 Thomas M et al.lancet Oncol 2008; 9; GLCCG study schema
30 GLCCG study Progression Free Survival Overall survival Thomas M et al.lancet Oncol 2008; 9;
31 GLCCG study clinical outcomes Thomas M et al.lancet Oncol 2008; 9; Table from Martins RG et al. JNCCN 2012; 10:
32 Ramnath N et al. Chest 2013; 143(5) (Suppl): e314s-e340s
33 Thomas M et al.lancet Oncol 2008; 9;
34 Conclusions 1. Lobectomy after neoadjuvant treatment may offer survival benefit for selected patients after neoadjuvant chemoradiotherapy, especially for those patients with nodal downstaging Pneumonectomy after induction should only be performed in a high volume center with demonstrated low mortality rate for pneumonectomy
35 Point #4 Neoadjuvant chemoradiotherapy does not offer clear survival advantage over neoadjuvant chemotherapy alone
36 Pre-operative chemotherapy in stage III NSCLC: Total of 755 pts treated in 11 trials using neoadjuvant chemotherapy Median survival of 19 months Martins RG et al. JNCCN 2012; 10:
37 Pre-operative chemoradiotherapy in stage III NSCLC: 627 patients treated in 11 phase 2 trials assessing concurrent CRT Median survival of 16 months Martins RG et al. JNCCN 2012; 10:
38 Neoadjuvant CRT vs chemo alone Is induction CRT superior to induction chemo? Shah et al: Review of 7 studies that met criteria for analysis, including 1 RCT, 1 phase II study, 3 retrospective reviews, 2 published abstracts of RCT s None of the studies demonstrated survival benefit to adding induction RT to induction chemo Meta-analysis performed on retrospective studies also did not demonstrate survival benefit Shah AA Ann Thorac Surg 2012; 93(6):
39 Preoperative chemotherapy vs chemoradiotherapy for stage III NSCLC Shah AA Ann Thorac Surg 2012; 93(6):
40 Forest plots of overall survival of patients in (A)RCT and in (B) retrospective studies comparing induction chemotherapy vs CRT A. Randomized controlled studies B. Retrospective studies Shah AA Ann Thorac Surg 2012; 93(6):
41 Advantages of induction chemo over CRT 1. Ability to deliver higher doses of pre-operative systemic chemotherapy 2. In vivo assessment of biology of the tumor 3. Interruption of potentially curative doses of chemoradiation for surgical exploration may be detrimental for those patients show tumors are then shown to be unresectable 4. Some studies (but not all) show lower complication rates when pre-operative chemo alone is used compared to preoperative CRT 5. Pre-op RT may be associated with pneumonitis and fibrosis as well as cardiac dysfunction, all of which may contribute to post-operative complications
42 Conclusions: point 4 Neoadjuvant chemoradiotherapy does not offer clear superiority over neoadjuvant chemotherapy alone, based on pooled results of multiple phase II studies There is a trend toward higher perioperative morbidity and mortality when neoadjuvant radiation is added
43 Point #5 Response to neoadjuvant treatment predicts favorable prognosis after surgery Although the rate of mediastinal clearance is only moderate with neoadjuvant chemotherapy alone, those patients have superior to survival compared to patients without nodal response to neoadjuvant treatment
44 Data from randomized phase II study Betticher et al: Multicenter phase II study enrolled 90 pts with pathologically confirmed IIIA N2 disease All pts received 3 cycles neoadjuvant docetaxel and cisplatin Overall response rate 66% Pathologic CR occurred in 15% pts Pathologic downstaging to N0 status was observed in 31% patients and to N1 status in 29% Betticher DC et al. J Clin Oncol 2003; 21:
45 Patients with downstaging to N0-1 status at surgery had 3 year survival of 61% and median survival of 33 mo Patients with persistent N2 disease had 11% survival at 3 years, median survival 16.2 months Betticher DC et al. J Clin Oncol 2003; 21:
46 Betticher DC et al. J Clin Oncol 2003; 21:
47 Retrospective data: Predictive value of nodal status at surgery Brigham and Women s Hospital series of all patient who underwent surgery for stage IIIA N2 NSCLC 103 patients received neoadjuvant therapy Preop treatment consisted of platinum based chemotherapy (76), radiotherapy (18) or chemoradiation (9) Operations included pneumonectomy in 38, bilobectomy in 6, and lobectomy in 59 R Bueno et al. Ann Thorac Surg 2000; 70:
48 Brigham and Women s Hospital series 29 patients patients who were downstaged to N0 with 5 year survival of 35.8% 74 patients with persistent N1 or N2 disease had 5 year survival of 9% R Bueno et al. Ann Thorac Surg 2000; 70:
49 Brigham and Women s Hospital series Cancer free survival based on nodal status at surgery Cancer free survival based on histology R Bueno et al. Ann Thorac Surg 2000; 70:
50 Point #6 Poor response to neoadjuvant treatment predicts for poor prognosis A. Patients with persistent pathological N2 disease after neoadjuvant treatment have 5 year survival rates of 9 to 29%, with average of 16% among 8 series B. Patients with lack of response after induction chemotherapy have average 5 year survival of 14% and median survival of 17 months among 17 series
51 Ramnath N et al. Chest 2013; 143(5) (Suppl): e314se340s
52 Ramnath N et al. Chest 2013; 143(5) (Suppl): e314se340s
53 Point #7 Patients with occult/unsuspected N2 disease and who undergo surgery have more favorable survival compared to patients with preoperatively detected N2 disease
54 Occult N2 disease Patients with cn0-n1, single station involvement, and T1/T2 tumors have better prognosis with average 5 year survival of 25-30% Multistation involvement, cn2 by CT scan, multilevel N2, T3 tumors or subcarinal nodal involvement: predict worse survival (5 year survival approximately 15%) Detterbeck F. J Thor Oncol 2008; 3(3):
55 Retrospective cohort study: survival of patients with unsuspected N2 disease Cerfolio et al: Retrospective review of prospective database with total of 148 pts; all pts with preoperative clinical stage of N0 or N1 48% underwent RUL lobectomy 93% received adjuvant chemotherapy 13% received adjuvant RT also Overall 5 yr survival of 35% Cerfolio RJ and Bryant AS. Ann Thorac Surg 2008; 86: 362-7
56 Survival of patients with unsuspected N2 disease 5 yr OS for patients with single station N2 vs multistation N2 involvement: 40% vs 25% Cerfolio RJ and Bryant AS. Ann Thorac Surg 2008; 86: 362-7
57 Conclusions: Surgery has no role in the treatment of the following subgroups of patients with N2 disease: A. Patients with bulky or fixed multistation N2 disease B. Patients without response after neoadjuvant treatment C. Patients who require pneumonectomy after neoadjuvant treatment (unless performed in a high volume center with demonstrated low mortality rate for pneumonectomy)
58 Conclusions: Surgery does have a role in the treatment of certain favorable subgroups of patients with IIIA N2 disease: A. Patients who are candidates for lobectomy after neoadjuvant treatment B. Patients with nodal downstaging and/or overall response after neoadjuvant treatment C. Patients with unsuspected/occult N2 disease
59 Ongoing controversies How is resectable vs unresectable defined Best neoadjuvant treatment (chemotherapy vs chemoradiation): No clear advantage in phase III randomized studies for either approach over the other Directions for future: Improvement in systemic treatments: role of molecularly customized treatment Better radiotherapy techniques
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationNeo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationSurgical Approaches to Locally Advanced NSCLC. Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX
Surgical Approaches to Locally Advanced NSCLC Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX Keep it real simple. Do one thing and do it the best you can. -Harry
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationTreatment of Stage III Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationTratamiento Multidisciplinar del CNMP Localmente Avanzado. Luis Paz-Ares
Tratamiento Multidisciplinar del CNMP Localmente Avanzado Luis Paz-Ares Indice Definición & Estadios Estadio IIIA N2 Estadio IIIB (y N2 irresecables) Conclusiones Indice Definición & Estadios Estadio IIIA
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationDefinitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
pissn 1598-2998, eissn 2005-9256 Original Article http://dx.doi.org/10.4143/crt.2014.144 Open Access Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA
More informationSagar Damle, MD University of Colorado Denver May 23, 2011
Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationsurgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
More informationMalignant Pleural Mesothelioma COMBINED TREATMENT
Malignant Pleural Mesothelioma COMBINED TREATMENT Federica Grosso incidence Italy
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationInduction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer
Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD, PhD, Mihir Gandhi, MS, Mathias Worni, MD, Ricardo
More informationThe Management of Patients With Stage IIIA Non Small Cell Lung Cancer With N2 Mediastinal Node Involvement
Original Article 599 The Management of Patients With Stage IIIA Non Small Cell Lung Cancer With N2 Mediastinal Node Involvement Renato G. Martins, MD, MPH a ; Thomas A. D Amico, MD b ; Billy W. Loo Jr,
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationVAMLA/TEMLA. Todd L. Demmy
VAMLA/TEMLA Todd L. Demmy Disclosures/ Questions Objectives - Staging Learn new lymphadenectomy (LA) results: Video-Assisted Mediastinal (VAMLA) Transcervical Extended Mediastinal (TEMLA) Compare with
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationIs consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationIn the United States, more than 220,000 new patients are
Original Article National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non Small-Cell Lung Cancer Aalok P. Patel, BS,* Traves D. Crabtree, MD,* Jennifer M. Bell, BSN,* Tracey
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationIs surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement?
doi:10.1510/icvts.2011.267872 Interactive CardioVascular and Thoracic Surgery 13 (2011) 303-310 www.icvts.org Best evidence topic - Thoracic oncologic Is surgery indicated in patients with stage IIIa lung
More informationPerioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer
Original Article Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer Jessica Glover 1, Frank O. Velez-Cubian 2, Kavian
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationNeoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
Review Article Page 1 of 9 Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified? René-Olivier Mirimanoff Professor Emeritus
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationNeoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients
Neoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients Anthony W. Kim, MD, Michael J. Liptay, MD, Philip Bonomi, MD, William H. Warren, MD, Sanjib Basu,
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationShort-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More information